Affiliation:
1. Department of Industrial and Materials Science, Chalmers University of Technology, Gothenburg, Sweden
2. Department of Mechanical Engineering, Technical University of Denmark, Kongens Lyngby, Denmark
3. Pharmaceutical Technology and Development, AstraZeneca Gothenburg, Mölndal, Sweden
Abstract
Emerging research within the field of personalised medicines has aimed to enhance patient treatment through the use of pharmaceutical products that are customised to the individual needs and preferences of the patient. The currently dominant production platforms of pharmaceutical products, however, regard a mass production paradigm and are thus unfeasible for the production and provision of personalised medicines. The production platforms are not designed or are intended for a customisation context. Operating such a context with the current supply chain entails challenges such as increasing costs, time to patient and efforts in quality assurance activities. To address these challenges, this paper presents four reconfigured pharmaceutical supply chain designs. A qualitative operational performance assessment elicits the strengths and weaknesses of the respective supply chain design operating in a customisation context. The results suggest that a later point of variegation, that is, the point in the supply chain where the final customisation is achieved, can relieve the operational effort of the stakeholders in the supply chain while providing the benefits of personalised medicines, that is, an enhanced treatment outcome of the patient. A trade-off remains, however, between the supply chain’s decreased operational effort and degree of necessary reconfigurations, such as introducing new functions to stakeholder operation, reallocating activities to other stakeholders or educating stakeholders.
Funder
chalmers tekniska högskola
Göran Wallberg stiftelse
Subject
Computer Science Applications,General Engineering,Modeling and Simulation
Reference39 articles.
1. Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
2. Understanding the pharmaceutical value chain
3. Deciding on the total number of product architectures
4. Bhasin H (2019a) Business model of walmart – How does walmart make money? Marketing91. Available at: https://www.marketing91.com/business-model-of-walmart/ (accessed 24 June 2020).
5. Bhasin H (2019b) Business model of Dell – How does Dell make money? Marketing91. Available at: https://www.marketing91.com/business-model-of-dell/ (accessed 24 June 2020).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献